|
DISEASE |
VACCINE |
CHEMOTHERAPY (Rx) |
CHEMOPROPHYLAXIS (Px) |
COMMENTS |
|
|
|
|
|
|
|
Anthrax |
Bioport vaccine (licensed)
0.5 mL SC @ 0, 2, 4 wk, 6, 12, 18 mo then annual boosters |
Ciprofloxacin 400 mg IV q
8-12 h |
Ciprofloxacin 500 mg PO bid x
4 wk If unvaccinated, begin initial doses of vaccine |
Potential alternates for Rx:
gentamicin, erythromycin, and chloramphenicol |
|
|
|
Doxycycline 200 mg IV, then
100 mg IV q 8-12 h |
Doxycycline 100 mg PO bid x 4
wk plus vaccination |
|
|
|
|
Penicillin 2 million units IV
q 2 h |
|
PCN for sensitive organisms
only |
|
|
|
|
|
|
|
Cholera |
Wyeth-Ayerst Vaccine 2 doses
0.5 mL IM or SC @ 0, 7-30 days, then boosters Q 6 months |
Oral rehydration therapy
during period of high fluid loss |
|
Vaccine not recommended for
routine protection in endemic areas (50% efficacy, short term) |
|
|
|
Tetracycline 500 mg q 6 h x 3
d |
|
Alternates for Rx:
erythromycin, |
|
|
|
Doxycycline 300 mg once, or
100 mg q 12 h x 3 d |
|
trimethoprim and
sulfamethoxazole, and furazolidone |
|
|
|
Ciprofloxacin 500 mg q 12 h x
3 d |
|
Quinolones for tetra/doxy
resistant strains |
|
|
|
Norfloxacin 400 mg q 12 h x 3
d |
|
|
|
|
|
|
|
|
|
Q Fever |
IND 610 - inactivated whole
cell vaccine given as
single 0.5 ml s.c. injection |
Tetracycline 500 mg PO q 6 h
x 5-7 d |
Tetracycline start 8-12 d
post-exposure x 5 d |
Currently testing vaccine to
determine the necessity of skin testing prior to use. |
|
|
|
Doxycycline 100 mg PO q 12 h
x 5-7 d |
Doxycycline start 8-12 d
post-exposure x 5 d |
|
|
|
|
|
|
|
|
Glanders |
No vaccine available |
Antibiotic regimens vary
depending on localization and severity of disease - refer to text |
Post-exposure prophylaxis may
be tried with TMP-SMX |
No large therapeutic human
trials have been conducted owing to the rarity of naturally occurring
disease. |
|
|
|
|
|
|
|
Plague |
Greer inactivated vaccine
(FDA licensed) is no longer available: 1.0 mL IM; 0.2 mL IM 1-3 mo later;
0.2 mL 5-6 mo after dose 2; 0.2 mL boosters @ 6,12, 18 mo after dose 3 then
q 1-2 years |
Streptomycin 30 mg/kg/d IM in
2 divided doses x
10 d (or gentamicin) |
Doxycycline 100 mg PO bid x 7
d or duration of exposure
Ciprofloxacin 500 mg PO bid x
7 d |
Plague vaccine not protective
against aerosol challenge in animal studies |
|
|
|
Doxy 200 mg IV then 100 mg IV
bid x 10-14 d |
Doxycycline 100 mg PO bid x 7
d
Tetracycline 500 mg PO qid x
7 d |
Alternate Rx:
trimethoprim-sulfamethoxazole |
|
|
|
Chloramphenicol 1 gm IV qid x
10-14 d |
|
Chloramphenicol for plague
meningitis |
|
Tularemia |
IND - Live attenuated
vaccine: one dose by scarification |
Streptomycin 30 mg/kg IM
divided BID x 10-14 d |
Doxycycline 100 mg PO bid x
14 d |
|
|
|
|
Gentamicin 3-5 mg/kg/d IV x
10-14 d |
Tetracycline 500 mg PO QID x
14 d |
|
|
|
|
|
|
|
|
Brucellosis |
No human vaccine available |
Doxycycline 200 mg/d PO plus
rifampin 600-900 mg/d PO x 6 wk |
Doxycycline and rifampin x 3
wk |
Trimethoprim-sulfamethoxazole
may be substituted for rifampin; however, relapse may reach 30% |
|
|
|
Ofloxacin 400/rifampin 600
mg/d PO x 6 wks |
|
|
|
|
|
|
|
|
|
Viral encephalitides |
VEE DOD TC-83 live attenuated
vaccine (IND): 0.5 mL SC x1 dose |
Supportive therapy:
analgesics and anticonvulsants prn |
NA |
TC-83 reactogenic in 20%
No seroconversion in 20%
Only effective against
subtypes 1A, 1B, and 1C |
|
|
VEE DOD C-84 (formalin
inactivated TC-83) (IND): 0.5 mL SC for up to 3 doses |
|
|
C-84 vaccine used for
non-responders to TC-83 |
|
|
EEE inactivated (IND):
0.5 mL SC at 0 & 28 d |
|
|
EEE and WEE inactivated
vaccines are poorly |
|
|
WEE inactivated (IND):
0.5 mL SC at 0, 7, and 28 d |
|
|
Immunogenic. Multiple
immunizations are required |
|
|
|
|
|
|
|
Viral Hemorrhagic
Fevers |
AHF Candid #1 vaccine
(x-protection for BHF) (IND)
|
Ribavirin (CCHF/arenaviruses)
30 mg/kg IV initial dose
15 mg/kg IV q 6 h x 4 d
7.5 mg/kg IV q 8 h x 6 d |
NA |
Aggressive supportive care
and management of hypotension very important |
|
|
RVF inactivated vaccine (IND) |
Passive antibody for AHF, BHF,
Lassa fever, and CCHF |
|
|
|
|
|
|
|
|
|
Smallpox |
Wyeth calf lymph vaccinia
vaccine (licensed): 1 dose by scarification |
No current Rx other than
supportive; Cidofovir (effective in vitro); animal studies ongoing |
Vaccinia immune globulin 0.6
mL/kg IM (within 3 d of exposure, best within 24 h) |
Pre and post exposure
vaccination recommended if > 3 years since last vaccine |
|
|
|
|
|
|
|
Botulism |
DOD pentavalent toxoid for
serotypes A - E (IND): 0.5 ml deep SC @ 0, 2 & 12 wk, then yearly boosters |
DOD heptavalent equine
despeciated antitoxin for serotypes A-G (IND): 1 vial (10 mL) IV |
|
Skin test for
hypersensitivity before equine antitoxin administration |
|
|
|
CDC trivalent equine
antitoxin for serotypes A, B, E (licensed) |
|
|
|
|
|
|
|
|
|
Staphylococcus
Enterotoxin B |
No vaccine available |
Ventilatory support for
inhalation exposure |
|
|
|
|
|
|
|
|
|
Ricin |
No vaccine available |
Inhalation: supportive
therapy G-I : gastric lavage, superactivated charcoal, cathartics |
|
|
|
|
|
|
|
|
|
T-2 Mycotoxins |
No vaccine available |
|
Decontamination of clothing
and skin |
|